Pub. Date : 2021 May
PMID : 33311577
5 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Here we found that background treatment with metformin diminished the SGLT2i-induced reductions in eGFR after 3 months of SGLT2i therapy in patients with type 2 diabetes and hypertension (-2.29 +- 0.90 vs -5.85 +- 1.27 mL/min/1.73 m2 for metformin users (n = 126) and nonusers (n = 97), respectively). | Metformin | epidermal growth factor receptor | Homo sapiens |
| 2 | Here we found that background treatment with metformin diminished the SGLT2i-induced reductions in eGFR after 3 months of SGLT2i therapy in patients with type 2 diabetes and hypertension (-2.29 +- 0.90 vs -5.85 +- 1.27 mL/min/1.73 m2 for metformin users (n = 126) and nonusers (n = 97), respectively). | Metformin | epidermal growth factor receptor | Homo sapiens |
| 3 | Next, we evaluated the interaction between metformin and RASis in the eGFR responses to SGLT2is. | Metformin | epidermal growth factor receptor | Homo sapiens |
| 4 | Under no background treatment with RASis, metformin abrogated the eGFR response to SGLT2is, but this response was preserved when RASis had been given along with metformin (decreases of 0.75 +- 1.28 vs. 4.60 +- 1.15 mL/min/1.73 m2 in eGFR, p = 0.028). | Metformin | epidermal growth factor receptor | Homo sapiens |
| 5 | In conclusion, metformin blunts the SGLT2i-induced decrease in eGFR, but coadministration of RASis ameliorates this response. | Metformin | epidermal growth factor receptor | Homo sapiens |